Metabolite characterisation of the peptide–drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS

References

• Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, Pasqualini R. 2004. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 6(3):275–284. doi: 10.1016/j.ccr.2004.08.018.
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stańczak A, Kautiainen A, Sandin P, Edlund PO. 2006. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rep. 58(3):341–352.
   PubMed Web of Science ®Google Scholar
• Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F. 1988. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol. 21(3):221–228. doi: 10.1007/BF00262774.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Solanki HK, Davidson M, Apostolopoulos V, Bojarska J. 2022. Peptide-drug conjugates: a new hope for cancer management. Molecules. 27(21):7232. doi: 10.3390/molecules27217232.
   PubMed Web of Science ®Google Scholar
• Cooper BM, Iegre J, O' Donovan DH, Ölwegård Halvarsson M, Spring DR. 2021. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem Soc Rev. 50(3):1480–1494. doi: 10.1039/d0cs00556h.
   PubMed Web of Science ®Google Scholar
• Farshbaf M, Khosroushahi AY, Mojarad-Jabali S, Zarebkohan A, Valizadeh H, Walker PR. 2020. Cell surface GRP78: an emerging imaging marker and therapeutic target for cancer. J Control Release. 328:932–941. doi: 10.1016/j.jconrel.2020.10.055.
   PubMed Web of Science ®Google Scholar
• Gao J, Chen H, Song H, Su X, Niu F, Li W, Li B, Dai J, Wang H, Guo Y. 2013. Antibody-targeted immunoliposomes for cancer treatment. Mini Rev Med Chem. 13(14):2026–2035. doi: 10.2174/1389557513666131119202717.
   PubMed Web of Science ®Google Scholar
• Ge X, Ma S, Yan S, Wu Y, Chen C, Tang C, Zhan Y, Bian Y-C, Shen K, Feng S, et al. 2023. Mass balance study of [(14)C]SHR0302, a selective and potent JAK1 inhibitor in humans. Xenobiotica. 53(2):69–83. doi: 10.1080/00498254.2023.2176267.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gronow M, Gopal U, Austin RC, Pizzo SV. 2021. Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders. IUBMB Life. 73(6):843–854. doi: 10.1002/iub.2502.
   PubMed Web of Science ®Google Scholar
• Hatsis P, Waters NJ, Argikar UA. 2017. Implications for metabolite quantification by mass spectrometry in the absence of authentic standards. Drug Metab Dispos. 45(5):492–496. doi: 10.1124/dmd.117.075259.
   PubMed Web of Science ®Google Scholar
• Hoppenz P, Els-Heindl S, Beck-Sickinger AG. 2020. Peptide-drug conjugates and their targets in advanced cancer therapies. Front Chem. 8:571. doi: 10.3389/fchem.2020.00571.
   PubMed Web of Science ®Google Scholar
• Ibrahim IM, Abdelmalek DH, Elfiky AA. 2019. GRP78: a cell’s response to stress. Life Sci. 226:156–163. doi: 10.1016/j.lfs.2019.04.022.
   PubMed Web of Science ®Google Scholar
• Jyrkäs J, Tolonen A. 2021. Hepatic in vitro metabolism of peptides; comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds. J Pharm Biomed Anal. 196:113921. doi: 10.1016/j.jpba.2021.113921.
   PubMed Web of Science ®Google Scholar
• Kang BR, Yang SH, Chung BR, Kim W, Kim Y. 2016. Cell surface GRP78 as a biomarker and target for suppressing glioma cells. Sci Rep. 6(1):34922. doi: 10.1038/srep34922.
   PubMedGoogle Scholar
• Lee YT, Tan YJ, Oon CE. 2018. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 834:188–196. doi: 10.1016/j.ejphar.2018.07.034.
   PubMed Web of Science ®Google Scholar
• Li J, Meng Q, Lei Y, Gu B, Liu Y, Lu W. 2011. Benzamide analogue-conjugated polyethylenimine for brain-targeting and gene delivery. J Drug Target. 19(9):814–820. doi: 10.3109/1061186X.2011.572975.
   PubMed Web of Science ®Google Scholar
• Lu G, Luo H, Zhu X. 2020. Targeting the GRP78 pathway for cancer therapy. Front Med (Lausanne)). 7:351. doi: 10.3389/fmed.2020.00351.
   PubMed Web of Science ®Google Scholar
• Ma L, Wang C, He Z, Cheng B, Zheng L, Huang K. 2017. Peptide-drug conjugate: a novel drug design approach. Curr Med Chem. 24:3373–3396.
   PubMed Web of Science ®Google Scholar
• Mross K, Maessen P, van der Vijgh WJ, Gall H, Boven E, Pinedo HM. 1988. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 6(3):517–526. doi: 10.1200/JCO.1988.6.3.517.
   PubMed Web of Science ®Google Scholar
• Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J. 2018. Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol. 233(9):6441–6457. doi: 10.1002/jcp.26435.
   PubMed Web of Science ®Google Scholar
• Passarella RJ, Spratt DE, van der Ende AE, Phillips JG, Wu H, Sathiyakumar V, Zhou L, Hallahan DE, Harth E, Diaz R. 2010. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res. 70(11):4550–4559. doi: 10.1158/0008-5472.CAN-10-0339.
   PubMed Web of Science ®Google Scholar
• Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E, Flavell DJ, et al. 2020. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 21(15):5510. doi: 10.3390/ijms21155510.
   PubMed Web of Science ®Google Scholar
• Ran D, Mao J, Shen Q, Xie C, Zhan C, Wang R, Lu W. 2017. GRP78 enabled micelle-based glioma targeted drug delivery. J Control Release. 255:120–131. doi: 10.1016/j.jconrel.2017.03.037.
   PubMed Web of Science ®Google Scholar
• Rivankar S. 2014. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 10(4):853–858. doi: 10.4103/0973-1482.139267.
   PubMed Web of Science ®Google Scholar
• Shadid M, Bowlin S, Bolleddula J. 2017. Catabolism of antibody drug conjugates and characterization methods. Bioorg Med Chem. 25(12):2933–2945. doi: 10.1016/j.bmc.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Słoczyńska K, Gunia-Krzyżak A, Koczurkiewicz P, Wójcik-Pszczoła K, Żelaszczyk D, Popiół J, Pękala E. 2019. Metabolic stability and its role in the discovery of new chemical entities. Acta Pharm. 69(3):345–361. doi: 10.2478/acph-2019-0024.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Vrettos EI, Karampelas T, Sayyad N, Kougioumtzi A, Syed N, Crook T, Murphy C, Tamvakopoulos C, Tzakos AG. 2021. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer. Eur J Med Chem. 211:113018. doi: 10.1016/j.ejmech.2020.113018.
   PubMed Web of Science ®Google Scholar
• Weiss RB. 1992. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 19:670–686.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. 2022. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl)). 135(5):584–590. doi: 10.1097/CM9.0000000000002108.
   PubMed Web of Science ®Google Scholar
• Yao JF, Yang H, Zhao YZ, Xue M. 2018. Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability. Curr Drug Metab. 19(11):892–901. doi: 10.2174/1389200219666180628171531.
   PubMed Web of Science ®Google Scholar
• Yu J, Deng P, Zhong D, Chen X. 2014. Identification of amino acid and glutathione N-conjugates of toosendanin: bioactivation of the furan ring mediated by CYP3A4. Chem Res Toxicol. 27(9):1598–1609. doi: 10.1021/tx5002145.
   PubMed Web of Science ®Google Scholar